Latest Royalty Income News

LCL Resources has secured a A$14 million cash deal plus royalty rights by divesting its Colombian projects to Tiger Gold Corporation, while advancing promising exploration programs in Papua New Guinea.

Gullewa Limited reports significant progress in its mining and property ventures, including a major drilling campaign and lot sales, setting the stage for an updated resource estimate.

Fitzroy River Corporation reported steady royalty income for the March 2025 quarter despite operational suspensions at Buru and ongoing geopolitical risks impacting commodity markets. Key project updates include Bowdens Silver’s development application progress and Federation Mining’s Snowy River feasibility study.

New Age Exploration has finalized the sale of its Lochinvar Metallurgical Coal Project, entering a royalty agreement that could yield up to A$15 million, while sharpening its focus on gold and lithium assets in Australia and New Zealand.

Anagenics Limited’s licensed brand Bouf Haircare is outperforming expectations with strong early sales and promising royalty returns, signaling robust growth potential for the company’s intellectual property portfolio.

Juno Minerals has agreed to sell its Mount Mason DSO Hematite Project to Gold Valley Yilgarn for A$6 million plus a 2% royalty, unlocking cash and future income while focusing on its flagship Mount Ida Magnetite Project.

Anagenics Limited’s proprietary hair regrowth technology powers the newly launched Bouf Haircare brand, which has achieved over $500,000 in sales in its first week, setting the stage for a lucrative royalty stream.

Emmerson Resources’ joint venture partner Tennant Mining has begun commercial gold production at the Nobles Project near Tennant Creek, setting the stage for potential royalty payments and future development opportunities.

Korab Resources has extended the completion date for the sale of its Geolsec mineral lease, securing higher royalty rates in the process. This move reshapes the financial terms of a key transaction tied to its Northern Territory phosphate project.

Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.

The Australian Wealth Advisors Group has deepened its Equity Partnership Scheme with strategic stakes in Oneledger and B2B Invest, setting up royalty revenue streams that align with its expansion in financial services.

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.